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Intensive research has demonstrated that extracellular
matrix (ECM) molecules and growth factors (GF) colla-
borate at many different levels. The ability of ECM to
modulate GF signals has important implications in
tissue formation and homeostasis as well as novel
therapies for acute and chronic wounds. Recently, a
number of GF-binding sites was identified in fibronec-
tin (FN) and was shown to provide another layer of
regulation on GF signaling. Here, we review these new
findings on FN interaction with GF in the context of
general ways ECM molecules regulate GF signaling.
Journal of Investigative Dermatology (2014) 134, 895–901; doi:10.1038/
jid.2013.484; published online 12 December 2013
INTRODUCTION
Extracellular matrix (ECM) is composed of secreted molecules
(glycoproteins, collagens, glycosaminoglycans, and proteogly-
cans) that constitute the cell microenvironment (Hynes, 2009).
ECM provides structural support and segregation for different
tissues in vivo. In the skin, it is essential to the tensile strength
and flexibility in the dermis and basement membrane (Kim
et al., 2011). The basement membrane also acts as a
mechanical barrier to cell migration into and out of the
epidermis and as a filter of fluid and solute exchange.
However, ECM provides much more than just mechanical
and structural support. Multiple specific domains in ECM can
bind interacting partners such as other ECM molecules, GFs,
cell ECM receptors, e.g., integrins, and other cell surface
receptors including some GF receptors. Through such
domains, ECM regulates the nature, intensity, and duration
of GF signaling. This in turn determines cell behavior, polarity,
migration, differentiation, proliferation, and survival (Legate
et al., 2009; Ivaska and Heino, 2011).
Many clinical trials in GF-based tissue engineering have
been largely disappointing. Recently, preclinical studies have
shown benefit when GF carriers, such as ECM GF-binding
domains, were included in tissue-engineering constructs
(Ghosh et al., 2006; Discher et al., 2009; Martino and
Hubbell, 2010; Martino et al., 2013). These data underline
the importance of spatial and temporal regulation of GF
signaling to achieve tangible therapeutic effects. Thus, it is
critical to understand mechanisms by which ECM can regulate
GF signaling in both normal and pathological conditions.
Here, we review some new findings on fibronectin (FN)
interactions with GF in the context of general ways ECM
can modulate GF signaling. A more detailed description of
ECM and GF interactions can be found in an earlier review by
our group (Macri et al., 2007).
ECM CAN REGULATE GF SIGNALING BASED ON ECM-
GF BINDING
An increasing number of GFs, including IGF, fibroblast growth
factor-b, transforming growth factor (TGF)-b, hepatocyte growth
factor, and platelet-derived growth factor (PDGF), have been
found to associate with the ECM through growth factor (GF)-
binding sites (Hynes, 2009). Some of these GF-binding sites are
conserved across different ECM proteins, e.g., von Willibrand
consensus domain in collagen II binds TGF-b1 and BMP-2;
heparin II domain in FN binds fibroblast growth factor, VEGF,
and PDGF (Wijelath et al., 2006; Martino and Hubbell, 2010);
and the FN first type III repeat (FNIII1) binds PDGF-BB (Lin et al.,
2011). A generally held view is that ECM acts as a sink or
reservoir for GFs and may assist in establishing stable gradients of
GFs bound to ECM. In addition, GFs bound to ECM (as a solid-
phase ligand) can generate different signals compared with their
soluble form (Mohammadi et al., 2005). Proteolytic processing of
ECM can release matrix-sequestered GFs during injury or
inflammation (Arroyo and Iruela-Arispe, 2010) inducing rapid
and localized changes in the activity of these GFs. Some of these
GF-binding domains are cryptic and will only be exposed
upon proteolytic processing or by the tension force generated
by cells (Lin and Clark, unpublished observations).
ECM as reservoir for GF
There is increasing evidence for specific, direct binding of GFs
to ECM in general (Macri et al., 2007) and to multiple GF-
binding domains in FN (Wijelath et al., 2006; Martino and
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Hubbell, 2010; Lin et al., 2011). The ECM can serve as a GF
reservoir and increase its local bioavailability (Figure 1a).
Hepatocyte growth factor binds both FN and vitronectin and
forms complexes with hepatocyte growth factor receptor and
integrins, leading to enhanced cell migration (Rahman et al.,
2005). Similarly, VEGF binds to specific FN type III domains in
both FN and tenascin-C. Using recombinant FN domains, the
C-terminal heparin-II domain of FN (FNIII13-14) was identified
as a key VEGF-binding site. Mutation of the heparin-binding
residues on FNIII13-14 abolished VEGF binding, and peptides
corresponding to the heparin-binding sequences in FNIII13-14
inhibited VEGF binding to FN. These ECM associations with
VEGF synergize to promote cell proliferation (Wijelath et al.,
2006; Ishitsuka et al., 2009).
More recently, it was found that FN III12–14 binds most of
the GFs from the PDGF/VEGF and fibroblast growth factor
families and some GFs from the transforming growth factor-b
and neurotrophin families (Martino and Hubbell, 2010). In
fibrin matrices functionalized with FN III12–14, PDGF-BB-
induced smooth muscle spheroid sprouting was greatly
enhanced. Furthermore, enzymatic release of ECM-sequestered
GFs during inflammatory processes, including wound healing,
can release such GFs (Arroyo and Iruela-Arispe, 2010). Thus,
rapid and local GF-mediated activation of cellular functions
can occur without de novo synthesis (Cox and Erler, 2011).
Solid-phase presentation of GF
When tethered to a solid substrate, EGF is more potent than
soluble EGF in eliciting DNA synthesis (Kuhl and Griffith-
Cima, 1996) (Figure 1b). EGF presented in solid phase is not
internalized and degraded, but instead provides sustained
signaling. For example, tethered EGF promoted mesenchymal
stem cell (MSC) survival by causing sustained cell surface
EGFR activation (Rodrigues et al., 2013). Furthermore, the
ability of tethered EGF to restricted signaling to the cell surface
promoted osteogenic differentiation of multipotent marrow
stromal cells (Platt et al., 2009). Most interesting, addition of
soluble EGF to cells cultured on tethered EGF substrata
reduced osteogenic differentiation. Furthermore, soluble EGF
downregulated EGFR and HER2 demonstrating that soluble
EGF can modulate tethered EGF/EGFR interactions.
In a similar manner, FN-GF–binding domains (FNIII1, FNIII13-14,
and IIICS) enhanced PDGF-BB survival signals in FN-null fibro-
blasts only when they were surface bound (Lin et al., 2011).
These FN domains contain sequence similarities that bind PDGF-
BB (Lin et al., 2013) as well as VEGF, fibroblast growth factor-2,
and TGF-b1 (Lin et al., manuscript in preparation). Therefore,
ECM-tethered GFs are fine-tuned to generate enhanced and/or
distinct signals from their soluble counterparts (Figure 1b).
Formation of adhesion complexes
Growth factor receptors (GFR) and integrins have been shown
to form signaling complexes through various mechanisms
(Motegi et al., 2011; Fujita et al., 2012). Thus, it is also
possible that GF-binding domains in ECM proteins can serve
as the link that brings together GFR and integrin (Figure 1c) as
proposed previously by our group (Lin et al., 2011). For
example, the a5b1 cell-binding domain (FNIII9-10/FNIII8-11)
and a GF-binding domain (either FNIII1 or FNIII12-14/FNIII12-15)
only demonstrated synergistic effects when the binding
domains for a5b1 and GF were coupled or presented
on the same surface, hence presentation on two separate
surfaces did not suffice (Wijelath et al., 2006; Lin et al., 2011;
Martino et al., 2011). For example, FN-null fibroblasts
cultured on recombinant FNIII8-11 without a FN-GF-binding
domain (FNIII1 or FNIII12-15) demonstrated minimal
α β
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Figure 1. Extracellular matrix (ECM) regulation of growth factor (GF) signaling dependent on ECM-GF binding. (a) ECM serves as a reservoir of GF to spatially
regulate its bioavailability. (b) GF tethered to ECM through GF-binding domain is presented as solid-phase ligand that generates protracted signaling. (c) The
juxtaposition of GF-binding domain and integrin-binding site in ECM facilitates the formation of adhesion complexes, the structural basis for the synergistic
signaling of ECM and GF. (d) Proteolytic processing not only releases ECM sequestered GF; but also it generates bioactive peptides that can directly bind GF and
enhance GF signaling.
J Zhu and RAF Clark
Fibronectin at Select Sites Binds Multiple GFs
896 Journal of Investigative Dermatology (2014), Volume 134
metabolism and underwent autophagy at 24 hours even in the
presence of PDGF-BB (Lin et al., 2011). In contrast, FN-null
fibroblasts plated on FNIII8-11 contiguous with a FN-GF–
binding domain survived without, and proliferated with,
PDGF-BB. These results suggest that the mechanism of GF/
FN synergism is mediated outside of the cell by the formation
of a GF/FN complex requiring both the cell-binding and
VEGF-binding domains linked in a single-molecular unit. As
such proximity is important, ECM molecules, by virtue of their
ordered-domain organization, could act to organize focal
adhesion complexes that contain not only integrins, but also
GF receptors, in the plane of the membrane as previously
suggested by results from the Ingber (Plopper et al., 1995) and
Yamada (Miyamoto et al., 1996) groups. Such complexes
could enhance membrane-proximal regulation among
receptors and promote integration of transduced signals
(Hynes, 2009; Lin et al., 2011).
Tension force by cell exposes cryptic domain in ECM
ECM is not an inanimate, unchanging assemblage of col-
lagens, proteoglycans, and glycoproteins. Rather the ECM
undergoes constant remodeling, most obviously during devel-
opment, wound healing, and other repair processes. Further-
more, many ECM molecules are flexible and extendable.
Mechanical tension studies on FN suggest that while eliminat-
ing normally exposed sites, cell-driven extension of FN can
expose cryptic sites that are not available in its native state
(Vogel, 2006). Indeed, FN fibrillogenesis requires strain on
FNIII1 and FNIII10 to expose cryptic sites (Zhong et al., 1998).
Such cell-driven strain on FN requires a5b1 binding to the FN
central cell-binding domain (FNIII9-10) (Mosher et al., 1992)
that is normally exposed on FN in a relaxed state (Vogel,
2006). Two classes of VEGF-binding sites on FN have been
identified (Mitsi et al., 2006). One is constitutively available,
whereas the availability of the other was modulated by the
conformational state of FN. Atomic force microscopy studies
revealed that heparin and hydrophilic substrates promoted an
extended conformation of FN, leading to increased VEGF
binding. Treatment of the complex endothelial ECM with
heparin also increased VEGF binding, suggesting that heparin/
heparan sulfate might regulate VEGF interactions within the
ECM by controlling the structure and organization of FN
matrices. Recent results from our laboratory also strongly
support the need of cell tension on FN to expose a cryptic
FN peptide for optimal cell survival on intact FN (Lin and
Clark, unpublished observations).
ECM peptides as co-factor of GF
In venous thrombus resolution, proteolytic fragments of FN,
which contain a VEGF-binding site, are expressed in a distinct
spatial and temporal pattern (Evans et al., 2012). Thus, FN
may influence capillary morphogenesis by the generation of
fragments that modulate VEGF-stimulated proliferation,
migration, and protease activation (Figure 1d). An analysis of
FN fragments (Fnf) generated by proteolytic processing from
matrix metalloprotease-2 (MMP-2) showed that Fnf of 30-kDa
and 120-kDa size positively affected proliferation of micro-
vascular cells but not macrovascular cells (Grant et al., 1998).
Furthermore, a 45-kDa gelatin-binding fragment of FN-
inhibited retinal endothelial cell proliferation but stimulated
pericyte and smooth muscle cell proliferation. Our group has
recently identified a bioactive FN peptide P12 from FNIII1 (Lin
et al. 2013, in press) that is theoretically released during
proteolysis as part of a larger fragment. Soluble P12 binds
PDGF-BB with high affinity (dissociation constant [KD] in the
nanomolar range) and can synergistically promote human
dermal fibroblast cell survival by augmenting PDGFR
activation and survival signals, i.e., Akt phorphorylation.
Moreover, P12 can also affect the PDGF-BB/PDGFR route of
endocytosis (Zhu et al., 2013). When P12 was present,
GFP-PDGFR co-localized with a macropinosome marker
(70 kDa dextran). Results suggested that P12 shifted entry of
PDGF-BB from clathrin/caveolin-mediated endocytosis to a
macropinocytosis-like pathway and thereby enhanced PDGFR
retention before lysosomal degradation. This introduces another
layer of interaction/synergism between ECM and GF signaling:
peptides generated by proteolytic processing of ECM can
regulate GF signaling by affecting GF endocytosis.
ECM CAN REGULATE GF SIGNALING INDEPENDENT OF
ECM-GF BINDING
All animal cells express receptors for GFs and ECM molecules
(Ivaska and Heino, 2011). GFs have cell surface receptors that
are linked to cellular signaling machinery, whereas adhesion
receptors link the cell cytoskeleton to their surroundings, i.e.,
ECM or other cells, and concomitantly activate signaling
pathways. Therefore, the fate of a cell is dependent on
signals generated by both receptor systems and the
integration between them. In this section, we discuss how
ECMs with different chemical and physical properties regulate
GF signaling independent of ECM-GF binding.
ECM and GF collaborate to activate the same pathway
Signals triggered by cell adhesion receptors, such as integrin,
are distinct but overlap with GFR signaling pathways
(Figure 2a). Signals from both receptor types can converge
on the same signaling pathways, e.g., Ras-MAPK pathway,
PI3K-Akt pathway, and Rho family GTPases (Schwartz and
Ginsberg, 2002; Yamada and Even-Ram, 2002). One of the
converging points between ECM and GF signaling is focal
adhesion kinase (FAK; Ilic et al., 1997). It was well
established that integrin-mediated cell attachment to ECM
triggers FAK activation that is required for integrin-stimulated
signaling (Sieg et al., 1999). However, FAK is required to
integrate, at least some, integrin and GF signals (Sieg et al.,
2000). Cells deprived of FAK are refractory to motility signals
from EGF, whereas re-expression of FAK rescues these
defects. At the same time, efficient EGF-stimulated mig-
ration also requires FAK for integrin-receptor clustering. In
another scenario, interaction between integrin and PDGFR
was demonstrated to be tissue transglutaminase dependent
(Zemskov et al., 2009).
ECM conditions cells for GF signaling
Anchorage dependence refers to a cell’s requirement of
adhesion for cell survival (Ruoslahti and Pierschbacher,
J Zhu and RAF Clark
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1987; Hadden and Henke, 2000). It is widely appreciated that
adherent cells depend on integrin-mediated adhesion for
responsiveness to GFs (Figure 2b). Loss of adhesion in normal
cells results in growth arrest or anoikis owing to impaired
signaling from GFs and cytokines (Danen and Yamada, 2001;
Schwartz and Assoian, 2001). For example, PDGF-stimulated
ERK2 activation in fibroblasts is dependent on attachment to
FN (Renshaw et al., 1997). However, recent reports suggest
that GF signaling can occur in anchorage-independent
conditions. For example, IGF1 signals were more clearly
detectable in anchorage-independent conditions (poly 2-
hydroxyethyl methacrylate (polyHEMA)-coated plates) than in
anchorage-dependent conditions. IGF signaling required avb3
integrin expression, and mutant IGF that cannot bind to avb3
was defective in inducing signals in polyhydroxyethyl-
methacrylate-coated plates. These results suggest that avb3–
IGF1 interaction, not avb3–ECM interaction, is essential for
IGF signaling (Fujita et al., 2012, 2013).
Besides anchorage dependence, different ECM can condition
the cell to generate different responses to the same GF. For
example, ligation of a5b1 integrin to FN results in Rac
activation and cell cycle progression, whereas a2b1-mediated
adhesion to laminin in the same cells results in growth arrest
(Mettouchi et al., 2001; Cailleteau et al., 2010). As another
example, primary mammary epithelial cells treated with insulin
are protected from cell death when plated on laminin, tenascin
C, or collagen IV, but not on collagen I (Merlo et al., 1995;
Streuli et al., 1995). The protective effects of insulin are
dependent on the ability of the integrin to promote activation
of Akt/PKB in collaboration with insulin receptors.
The physical property of ECM can also condition cells to
generate different responses (Discher et al., 2005). For
example, ECM stiffness has been recognized to provide
critical clues for stem cell differentiation (Discher et al.,
2009; Geiger et al., 2009). Cellular responses to mechanical
signals include differentiation, migration, proliferation, and
alterations in cell–cell and cell–matrix adhesion. This ‘‘stiff-
ness sensing’’ has been demonstrated in a variety of cell types
including endothelial cells (Califano and Reinhart-King, 2010),
smooth muscle cells (Engler et al., 2004), transformed cells
(Levental et al., 2009), and stem cells (Engler et al., 2007).
Stiff substrates increase both focal adhesion and cytoskele-
tal organization (Engler et al., 2004; Genes et al., 2004;
Yeung et al., 2005; Wang, 2009) and conditions cells to GF
stimulation. For example, matrix stiffening sensitizes
epithelial cells to EGF and enables loss of contact inhibition
(Kim and Asthagiri, 2011). A moderate (4.5-fold) stiffening of
matrix reduces threshold amount of EGF needed to override
contact inhibition. ECM stiffness also primes the TGF-b
pathway to promote chondrocyte differentiation (Allen
et al., 2012).
ECM can activate GFR in the absence of GF
In the absence of GFs, some ECMs can activate GFR on their
own through integrin signaling. For example, FNIII9-10 (the
Arg–Gly–Asp (RGD)-containing central cell-binding domain)
mediates FN binding to cells and generates important survival
signals either through a5b1 integrin (Zhang et al., 1995) or
through activating GFR (Shen and Kramer, 2004).
Furthermore, cell adhesion to FN induces a5b1-dependent
phosphorylation of PDGFR-b in the absence of GF stimulation
(Veevers-Lowe et al., 2011). Similarly, GF-independent
activation of c-Met by FN binding to a5b1 occurs in various
systems (Wang et al., 2001; Mitra et al., 2011). In another
system, activation of integrin a5/b1 by FN could also activate
EGFR independent of EGF (Kuwada and Li, 2000). This EGFR
α β α β
α β
Figure 2. Extracellular matrix (ECM) regulation of growth factor (GF) signaling independent of ECM-GF binding. (a) ECM and GF generate signals that
activate the same pathway synergistically. (b) The type or stiffness of ECM pre-conditions the cell and regulates the outcome of GF signaling. (c) ECM can also
activate growth factor receptor (GFR) in the absence of GF either through integrin or through direct binding to GFR. (d) ECM generates signals through integrin
to regulate the expression level (recycling) of GFR or GF.
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transactivation was proposed to be mediated by Src-
dependent Tyr-845 phosphorylation on EGFR (Balanis and
Carlin, 2012). In addition, some bioactive domains within
other ECM molecules (matrikines) can activate GFR
independent of integrin binding (Tran et al., 2005;
Figure 2c). For example, EGF-like domains from laminin
(Schenk et al., 2003) or tenascin (Iyer et al., 2007) presented
as soluble ligands can bind to EGFR and stimulate signaling.
ECM signaling can regulate GF and GFR expression level
As an example of ECM regulation of GF level (Figure 2d), the
extra domain A of FN increases VEGF-C expression in colo-
rectal carcinoma (Xiang et al., 2012). Furthermore, blocking
b1-integrin signaling with antibody caused a downregulation
of EGFR expression level in mammary epithelial cells
cultured in three-dimensional basement membrane gels
(Wang et al., 1998). This does not happen when cells were
cultured in two-dimensional matrix, indicating that GFR and
integrin couple in a three-dimensional environment. EGFR
expression can be regulated by b1 integrin signaling
and is reduced when cells are detached from ECM (Reginato
et al., 2003). Also, cell adhesion to ECM inhibits PDGFR
degradation thus increases PDGFR (Baron and Schwartz,
2000) and a low concentration of RGD-mimetic promotes
VEGF-stimulated angiogenesis by increasing vascular
endothelial growth factor receptor-2 recycling (Ghosh et al.,
2006).
CONCLUSION AND FUTURE PERSPECTIVES
Intensive research has demonstrated that ECM and GF signal-
ing collaborate at many different levels. ECM signaling often
synergizes with GF signaling by activating the same pathways.
The type and stiffness of ECM condition the cell and can
regulate the outcome of GF signaling. Some ECM can activate
GFR in the absence of GF. Furthermore, expression level of
GFR can be regulated by ECM signaling.
Recently, many GF-binding domains have been discovered
in FN, introducing a new layer of interaction between ECM
and GF. First, FN acts as a reservoir of GF and thereby forms
GF gradients. Proteolytic processing of FN can release GF
deposited in FN while at the same time generate bioactive GF-
binding peptides. FN-tethered GFs are presented as solid-
phase ligand that retards GFR internalization regulating the
duration and outcome of GF signaling. Also, juxtaposition of
GF-binding domain and integrin-binding site in FN facilitates
formation of adhesion complex, a structural basis of ECM-GF
synergistic signaling. Cells exert tension force on FN that can
expose cryptic sites that activate GFR or bind GF. Recently our
laboratory demonstrated FN peptide could regulate GF/GFR
trafficking thus affecting GF signaling.
Difficult to heal or chronic wounds exhibit FN deficits and
GF abnormalities that likely contribute to their stalled progres-
sion. Wound healing strategies that incorporate both FN or
other ECM and GF may be beneficial for these wound types
and, indeed, therapies of only one type or the other have
generally proved disappointing (Agren and Werthen, 2007).
Future research designed to understand ECM regulation of GF
signaling in normal wound-healing process may provide
important insights in GF/ECM-based tissue engineering
(Schultz and Wysocki, 2009).
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